Investigating a new antibody treatment for HCMV infections
Official title: HCMV Therapeutic Antibody Safety Trial
Funded at Trellis Bioscience, INC. · NIH-10891737 · Data updated 2026-11-12
This study is testing a new treatment called TRL345, a special antibody that aims to help people, especially newborns and organ transplant patients, by fighting off infections from a virus called cytomegalovirus (HCMV) while keeping side effects low.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Trellis Bioscience, INC. NIH-funded |
| Lab location | 1 site (Redwood City, UNITED STATES) |
| Project start | July 1, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $998,144 |
| NIH project number | 5U44AI152970-03 |
| Project ID | NIH-10891737 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation include pregnant women at risk of HCMV transmission and patients undergoing bone marrow or organ transplants.
✕Less likely to help
Patients who are not at risk for HCMV infection or those who have already been treated for HCMV may not benefit from this research.
What this research studies
This research focuses on developing a monoclonal antibody (TRL345) to treat human cytomegalovirus (HCMV) infections, which can cause serious complications in newborns and patients undergoing organ transplants. The study aims to evaluate the safety and effectiveness of this antibody, which has shown promise in neutralizing various strains of HCMV. By using a highly specific antibody, the research seeks to minimize side effects associated with traditional treatments. Patients may be involved in trials to assess how well this new treatment works in preventing HCMV-related complications.
Why it matters
Potential benefit: If successful, this research could lead to a safer and more effective treatment for HCMV infections, potentially reducing the incidence of birth defects and complications in transplant patients.
How similar studies have gone: Previous research has shown success with monoclonal antibodies in treating viral infections, indicating a promising approach for this novel treatment.
Where this research is happening
-
Trellis Bioscience, INC.
Redwood City, United States Active
Researchers
- Principal investigator: Kauvar, Lawrence Michael — Trellis Bioscience, INC.
- Study coordinator: Kauvar, Lawrence Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.